Navigation Links
Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections
Date:10/25/2007

BOSTON, Oct. 25 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. announced today that it has closed the first tranche of a $40 million private financing. Aisling Capital led the round, with additional participation by new investors, D.E. Shaw and Boston Life Science Venture Corporation, and current investors, Nomura Phase4 Ventures, Novartis BioVentures, BioFund Ventures, HBM BioVentures, Lombard Odier Darier Hentsch, BioVeda Fund and Hercules Technology Growth Capital. The second and final tranche is expected to be closed in early 2008. Pacific Growth Equities served as placement agent for the financing.

Proceeds of the financing will be used primarily to advance Paratek's lead programs to develop broad-spectrum antibiotics, including two antibiotics for the treatment of resistant bacterial infections such as those caused by Methicillin-Resistant Staphylococcus aureus (MRSA). Recent media attention on the dramatic increase in invasive MRSA infections, as published in the October 17, 2007 issue of the Journal of the American Medical Association (JAMA), has highlighted the dire need for new antibiotics to combat these infections in both the hospital and community settings. Paratek has designed two broad- spectrum antibiotics that have been shown to work against susceptible bacteria found in most common infections, as well as antibiotic resistant bacteria such as MRSA, vancomycin-resistant Enterococci (VRE) and penicillin-resistant Streptococcus pneumoniae (PRSP).

Paratek's most advanced broad-spectrum antibiotic, PTK 0796, is currently being developed to treat serious, often life-threatening infections that require a hospital visit such as complicated skin and skin structure infections (cSSSI) and moderate to severe community-acquired pneumonias (CAP). Oral and intravenous (IV) forms of PTK 0796 are being studied in comparison to Zyvox(R) in an ongoing Phase 2 clinical study of patients with cSSSI. The study is anticipated to complete enrollment this
'/>"/>

SOURCE Paratek Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... REDMOND, Washington , 29 luglio 2015 /PRNewswire/ ... tedesco ha scoperto che l,ingestione quotidiana del probiotico ... microbiota intestinale umano e modifica la produzione intestinale ... insulina. Lo studio riguardava la somministrazione quotidiana di ceppo ... ATCC SD-5865) in compresse utilizzando il sistema di ...
(Date:7/29/2015)... FOREST, Calif. , July 29, 2015 ... ("Cryoport" or the "Company"), the leading provider ... life sciences industry, serving markets including immunotherapies, ... vaccine manufacturers, animal health, and reproductive medicine, ... the sale of common stock and warrants (the ...
(Date:7/29/2015)... Heska Corporation (NASDAQ: HSKA - News; ... diagnostic and other specialty veterinary products , today reported financial ... Second Quarter 2015 Highlights with Prior Year Comparison: ... $1.829 million, from $917 thousand. , Blood Analyzer and ... , Core Companion Animal revenue was up 19% to ...
Breaking Medicine Technology:È stato clinicamente dimostrato che il probiotico L. reuteri di Nutraceutix regola il metabolismo insulinico intestinale 2Cryoport Completes $6.8 Million Equity Capital Raise 2Cryoport Completes $6.8 Million Equity Capital Raise 3Heska Reports Financial Results for the Second Quarter of 2015 2Heska Reports Financial Results for the Second Quarter of 2015 3Heska Reports Financial Results for the Second Quarter of 2015 4Heska Reports Financial Results for the Second Quarter of 2015 5Heska Reports Financial Results for the Second Quarter of 2015 6Heska Reports Financial Results for the Second Quarter of 2015 7Heska Reports Financial Results for the Second Quarter of 2015 8
... First Prostate Cancer Patients in Clinical... -- TEL AVIV, Israel, August 31, 2010 ... ... ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
... Kendle (Nasdaq: KNDL ), a ... Mark J. Roseman, D.Sc., as the Company,s new ... effective immediately. Dr. Roseman brings to Kendle more ... strategic account development experience in the clinical services ...
Cached Medicine Technology:Elbit Imaging Announces Insightec Treats First Prostate Cancer Patients in Clinical Trials 2Elbit Imaging Announces Insightec Treats First Prostate Cancer Patients in Clinical Trials 3Elbit Imaging Announces Insightec Treats First Prostate Cancer Patients in Clinical Trials 4Elbit Imaging Announces Insightec Treats First Prostate Cancer Patients in Clinical Trials 5Elbit Imaging Announces Insightec Treats First Prostate Cancer Patients in Clinical Trials 6Elbit Imaging Announces Insightec Treats First Prostate Cancer Patients in Clinical Trials 7Elbit Imaging Announces Insightec Treats First Prostate Cancer Patients in Clinical Trials 8Elbit Imaging Announces Insightec Treats First Prostate Cancer Patients in Clinical Trials 9Kendle Appoints Mark J. Roseman, D.Sc., Senior Vice President and Chief Marketing Officer 2Kendle Appoints Mark J. Roseman, D.Sc., Senior Vice President and Chief Marketing Officer 3
(Date:7/29/2015)... Plainsboro, NJ (PRWEB) , ... July 29, 2015 ... ... Annual Convenient Healthcare and Pharmacy Collaborative for retail healthcare providers begins in ... ways pharmacists, nurse practitioners and physician assistants can work together to expand access ...
(Date:7/29/2015)... ... ... Abt Associates has named Selena Ramkeesoon, a strategic communications ... position, Ramkeesoon will help build and expand work in communications, and the dissemination ... decade at ICF International, most recently as a vice president. During her career, ...
(Date:7/29/2015)... ... 2015 , ... According to the The Media Post on July ... advertisements, for medicinal use are more likely to abuse the substance. A recent study ... is considered beneficial are more apt to use the substance, as opposed to their ...
(Date:7/29/2015)... TX (PRWEB) , ... July 29, 2015 , ... ... comprehensive information on the therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive ... new targets and MOAs to produce first-in-class and best-in-class products. Complete report on ...
(Date:7/29/2015)... LAUREL, NJ (PRWEB) , ... July 29, 2015 ... ... Certification’s (the Commission) CCM® credential for a five-year period, expiring November 30, 2019, ... its CCM credential by submitting an application demonstrating the program’s compliance with the ...
Breaking Medicine News(10 mins):Health News:Last Chance for Pharmacists, Nurse Practitioners, Physician Assistants in Retail Clinics to Register for Collaborative Learning Program 2Health News:Last Chance for Pharmacists, Nurse Practitioners, Physician Assistants in Retail Clinics to Register for Collaborative Learning Program 3Health News:Last Chance for Pharmacists, Nurse Practitioners, Physician Assistants in Retail Clinics to Register for Collaborative Learning Program 4Health News:Selena Ramkeesoon Joins Abt Associates as Vice President for Strategic Communications 2Health News:New Study Reveals Teens Use Marijuana More in States Where Marijuana Is Legalized 2Health News:New Study Reveals Teens Use Marijuana More in States Where Marijuana Is Legalized 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 2Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 3
... Oct. 27 (HealthDay News) -- People who live in poorer ... care are more likely to suffer a fatal stroke than ... The findings, published in the current issue of the ... efforts are needed, particularly in developing countries, the study authors ...
... News) -- Huge amounts of fatty acids that circulate in ... growth, a finding that may lead to new ways to ... after eating, triglyceride levels in Burmese pythons increased by more ... and oils. There was also an increase in the ...
... Rochelle, NY, October 27, 2011Bruce Beutler, MD, a co-recipient of ... describing a novel molecular mechanism that can cause the body ... is published online ahead of print in Journal of ... Mary Ann Liebert, Inc. ( www.liebertpub.com ) and is available ...
... A majority of Floridians (87%) believe it is important for ... research, according to a new state poll commissioned by Research!America. ... scientific research is important for Florida,s economy in terms of ... believe the state should lead in science and technology education ...
... master transcription factors determine the genes regulated by key ... to genes that are most relevant to each cell ... growth, differentiation, and death. RELEVANCE: ... from its neighbors and the environment that tweak gene ...
... hard up socially and financially during adolescence and early adulthood ... wear and tear in middle aged men and women, irrespective ... to Dr. Per E. Gustafsson from Ume University in Sweden ... time of transition into adulthood is linked to a rise ...
Cached Medicine News:Health News:Poorer Countries Have Higher Rates of Stroke, Study Finds 2Health News:Python Findings Shed Light on Human Heart Health 2Health News:Florida poll: Research important for state economy, jobs 2Health News:Florida poll: Research important for state economy, jobs 3Health News:How major signaling pathways are wired to our genome gives new insight into disease processes 2Health News:How major signaling pathways are wired to our genome gives new insight into disease processes 3Health News:Hard times during adolescence point to health problems later in life 2
... Plus with C-Flex combines optional ... the comfort of C-Flex.With the ... Plus with C-Flex offers a ... sleep therapy by taking the ...
... with the integrated Everest system. With ... system will be functional for hours ... integrated heated humidifier. The Everest heated ... nights use, and the reservoir is ...
Chase micro-hemocrit tubes are manufactured from soda lime glass, packed in plastic vials with reclosable snap-lock caps to maintain cleanliness....
... Vivid 3 system is designed to address ... performance, and offer an even wider range ... the OR. From color flow imaging with ... new Vivid 3 offers a wealth of ...
Medicine Products: